플러스100%마이너스

통합검색
닫기

KMCRIC 챗봇에게

질문하기!

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials.

Authors

Shishtar E, Sievenpiper JL, Djedovic V, Cozma AI, Ha V, Jayalath VH, Jenkins DJ, Meija SB, de Souza RJ, Jovanovski E, Vuksan V.

Journal

PLoS One.

Year

2014

Vol (Issue)

9(9)

Page

e107391.

doi

10.1371/journal.pone.0107391.

PMID

25265315

Url

http://www.ncbi.nlm.nih.gov/pubmed/25265315

MeSH

Keywords

한글 키워드

KMCRIC
Summary & Commentary

KMCRIC 비평 보기 +

Korean Study

Abstract

IMPORTANCE:
Despite the widespread use of ginseng in the management of diabetes, supporting evidence of its anti-hyperglycemic efficacy is limited, necessitating the need for evidence-based recommendations for the potential inclusion of ginseng in diabetes management.

OBJECTIVE:
To elucidate the effect of ginseng on glycemic control in a systematic review and meta-analysis of randomized controlled trials in people with and without diabetes.

DATA SOURCES:
MEDLINE, EMBASE, CINAHL and the Cochrane Library (through July 3, 2013).

STUDY SELECTION:
Randomized controlled trials ≥30 days assessing the glycemic effects of ginseng in people with and without diabetes.

DATA EXTRACTION:
Relevant data were extracted by 2 independent reviewers. Discrepancies were resolved by consensus. The Heyland Methodological Quality Score and the Cochrane risk of bias tool were used to assess study quality and risk of bias respectively.

DATA SYNTHESIS:
Sixteen trials were included, in which 16 fasting blood glucose (n = 770), 10 fasting plasma insulin (n = 349), 9 glycated hemoglobin (n = 264), and 7 homeostasis model assessment of insulin resistance (n = 305) comparisons were reported. Ginseng significantly reduced fasting blood glucose compared to control (MD =  -0.31 mmol/L [95% CI: -0.59 to -0.03], P = 0.03). Although there was no significant effect on fasting plasma insulin, glycated hemoglobin, or homeostasis model assessment of insulin resistance, a priori subgroup analyses did show significant reductions in glycated hemoglobin in parallel compared to crossover trials (MD = 0.22% [95%CI: 0.06 to 0.37], P = 0.01).

LIMITATIONS:
Most trials were of short duration (67% trials<12wks), and included participants with a relatively good glycemic control (median HbA1c non-diabetes = 5.4% [2 trials]; median HbA1c diabetes = 7.1% [7 trials]).

CONCLUSIONS:
Ginseng modestly yet significantly improved fasting blood glucose in people with and without diabetes. In order to address the uncertainty in our effect estimates and provide better assessments of ginseng's anti-diabetic efficacy, larger and longer randomized controlled trials using standardized ginseng preparations are warranted.

TRIAL REGISTRATION:
ClinicalTrials.gov NCT01841229.

국문초록

Language

영어

첨부파일